191 related articles for article (PubMed ID: 9433865)
1. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs.
Maetzel A; Ferraz MB; Bombardier C
Arthritis Rheum; 1998 Jan; 41(1):16-25. PubMed ID: 9433865
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis.
Kristiansen IS; Kvien TK; Nord E
Arthritis Rheum; 1999 Nov; 42(11):2293-302. PubMed ID: 10555023
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.
Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
Arthritis Rheum; 2000 Apr; 43(4):917-24. PubMed ID: 10765939
[TBL] [Abstract][Full Text] [Related]
5. A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac.
Morant SV; Shield MJ; Davey PG; MacDonald TM
Pharmacoepidemiol Drug Saf; 2002; 11(5):393-400. PubMed ID: 12271881
[TBL] [Abstract][Full Text] [Related]
6. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
7. [Is misoprostol effective in NSAID-induced gastrointestinal complications?].
Stucki G; Sangha O; Michel BA
Schweiz Med Wochenschr; 1996 Sep; 126(37):1573-8. PubMed ID: 8927962
[TBL] [Abstract][Full Text] [Related]
8. [Economic evaluation of the use of diclofenac/misoprostol in the treatment of osteoarticular diseases].
Soto Alvarez J
An Med Interna; 2000 Sep; 17(9):477-84. PubMed ID: 11100534
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.
Brown TJ; Hooper L; Elliott RA; Payne K; Webb R; Roberts C; Rostom A; Symmons D
Health Technol Assess; 2006 Oct; 10(38):iii-iv, xi-xiii, 1-183. PubMed ID: 17018227
[TBL] [Abstract][Full Text] [Related]
10. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Spiegel BM; Chiou CF; Ofman JJ
Arthritis Rheum; 2005 Apr; 53(2):185-97. PubMed ID: 15818647
[TBL] [Abstract][Full Text] [Related]
11. Prevention of gastrointestinal complications associated with nonsteroidal antiinflammatory drugs.
Agrawal NM; Aziz K
J Rheumatol Suppl; 1998 May; 51():17-20. PubMed ID: 9596550
[TBL] [Abstract][Full Text] [Related]
12. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
[TBL] [Abstract][Full Text] [Related]
13. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Targownik LE; Metge CJ; Leung S; Chateau DG
Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
[TBL] [Abstract][Full Text] [Related]
14. Rheumatologists' adherence to guidelines for misoprostol use in patients at high risk for nonsteroidal antiinflammatory drug gastropathy.
Cibere J; Sibley JT; Haga M
J Rheumatol; 2002 Feb; 29(2):339-46. PubMed ID: 11838854
[TBL] [Abstract][Full Text] [Related]
15. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
Chan FK; Graham DY
Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
[TBL] [Abstract][Full Text] [Related]
16. Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs.
Jacobsen RB; Phillips BB
Ann Pharmacother; 2004 Sep; 38(9):1469-81. PubMed ID: 15213313
[TBL] [Abstract][Full Text] [Related]
17. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Goldstein JL; Huang B; Amer F; Christopoulos NG
Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
[TBL] [Abstract][Full Text] [Related]
18. Complications of nonsteroidal antiiflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health center.
Bakowsky VS; Hanly JG
J Rheumatol; 1999 Jul; 26(7):1557-63. PubMed ID: 10405945
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of misoprostol in the prophylaxis of gastroduodenal lesions induced by short-term nonsteroidal antiinflammatory drug therapy in elderly patients. A multicenter double-blind, placebo-controlled trial.
Piette F; Teillet L; Naudin R; Boichut D; Capron MH
Rev Rhum Engl Ed; 1997 Apr; 64(4):259-66. PubMed ID: 9178399
[TBL] [Abstract][Full Text] [Related]
20. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy: clinical and economic implications of a single-tablet formulation of diclofenac/misoprostol.
Goldstein JL; Larson LR; Yamashita BD
Am J Manag Care; 1998 May; 4(5):687-97. PubMed ID: 10179922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
